-
Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System
•
Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Beijing NatonTechnology Group Co., Ltd. The funds raised will be directed towards clinical studies and market promotion efforts. HuiKai Medtech’s Core Product…
-
Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug
•
Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving ethical approval to initiate a Phase II clinical study for its LT-01 (litazolid dry suspension). This development marks a significant step in the advancement of the company’s pipeline. LT-01: A Promising Oxazolidone Antibacterial DrugThe Category…
-
RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System
•
RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish a clinics-centered integrated system that spans the pharmaceutical industry, academia, and research fields, with a focus on antibody-drug conjugate (ADC) development. RemeGen’s ADC Achievements and PipelineRemeGen’s disitamab vedotin marked a significant milestone as the first…
-
Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the Netherlands, the United States, and China, has struck a partnership with Dr. Michael S. Diamond from Washington University School of Medicine in St. Louis. This collaboration aims to explore viral disease fields that are currently…
-
Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China
•
China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical Co., Ltd (SPH Kyuan), for a strategic partnership. According to the MoU, Everest and SPH Keyuan will collaborate to promote the import and channel distribution of Xerava (eravacycline)…
-
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
•
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study for its IBI351 monotherapy in advanced solid tumors at the American Association for Cancer Research (AACR) annual meeting. IBI351: A KRAS G12C Inhibitor Under AssessmentIBI351 (GFH925), a KRAS G12C inhibitor originated by GenFleet Therapeutics Inc.,…
-
National Center Reports Increase in Medical Device Adverse Event Reports for 2022
•
The National Center for Adverse Event Monitoring has released its national annual report regarding the use of medical devices in China. The report highlights key statistics and insights into the monitoring and management of adverse events associated with medical devices. Increase in Adverse Event Reports and CoverageIn 2022, the National…
-
China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog
•
The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have Jointly released a notification concerning the adjustment of the narcotics and psychotropic substances catalog in China. The updated catalog, which adds seven new varieties, is set to take effect on July 1, 2023. Details of…
